Apixaban Discontinuation Before Bladder Surgery
For bladder surgery, which carries a high bleeding risk, apixaban (Eliquis) should be stopped 3 days before the procedure (skip 4 doses) in patients with normal or mildly impaired renal function (CrCl ≥50 mL/min), or 4 days before surgery (skip 6 doses) in patients with moderate renal impairment (CrCl 30-50 mL/min). 1
Rationale Based on Bleeding Risk
Bladder surgery is classified as a high bleeding risk procedure due to the highly vascular nature of bladder tissue and the potential for significant hemorrhage. The goal is to achieve minimal or no residual anticoagulant effect (≤12-25%) at the time of surgery 1.
Timing Based on Renal Function
The discontinuation interval depends critically on kidney function because apixaban has 25% renal clearance, and its half-life is 7-8 hours in patients with normal renal function 1:
Normal or mild renal impairment (CrCl ≥50 mL/min): Last dose 3 days before surgery (skip 4 doses). This allows 4-5 drug half-lives to elapse, resulting in minimal residual anticoagulation 1
Moderate renal impairment (CrCl 30-50 mL/min): Last dose 4 days before surgery (skip 6 doses). The prolonged half-life in renal dysfunction necessitates extended interruption 1
The 2014 Canadian Cardiovascular Society guidelines align with this approach, recommending 2-3 days interruption for procedures with intermediate or high bleeding risk 2.
FDA Label Guidance
The FDA-approved prescribing information for Eliquis states that the drug should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding 3. However, this represents a minimum threshold, and the more conservative guideline-based approach of 3-4 days is preferable for high-risk procedures like bladder surgery.
Evidence Quality
The PAUSE study, a prospective management study of 3,007 patients, validated this standardized approach and demonstrated 30-day post-operative rates of major bleeding of only 1.35% and arterial thromboembolism of 0.16% in the apixaban cohort 4. This high-quality evidence supports the safety of standardized interruption without bridging anticoagulation.
Critical Pitfalls to Avoid
Do not use heparin bridging during the interruption period. Bridging anticoagulation is not generally required and may increase bleeding risk 3. The rapid onset of apixaban (peak effect in 3-4 hours) means it can be safely restarted postoperatively without bridging 1.
Do not continue apixaban for bladder procedures. While minimal bleeding risk procedures (dental work, skin biopsies) may proceed without interruption, bladder surgery's high vascularity and bleeding potential mandate discontinuation 5.
Special Considerations
For patients with severe renal impairment (CrCl 15-30 mL/min), though not specifically addressed in the primary guidelines for apixaban, extrapolation from rivaroxaban data suggests extending the interruption to 4-5 days may be prudent 1.
For urgent bladder surgery (within 24-48 hours), measuring apixaban-calibrated anti-Xa levels can guide decision-making about whether reversal agents are needed, though this testing is not widely available 4, 6.
Postoperative Resumption
After bladder surgery, resume apixaban 2-3 days postoperatively (48-72 hours) once adequate hemostasis is established 1. For patients at high thromboembolism risk, consider starting with a reduced dose of 2.5 mg twice daily for the first 2-3 days, then increasing to the full therapeutic dose 1.